Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Stauber, RE; Fauler, G; Rainer, F; Leber, B; Posch, A; Streit, A; Spindelboeck, W; Stadlbauer, V; Kessler, HH; Mangge, H.
Anti-HCV treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir is associated with increased bile acid levels and pruritus.
Wien Klin Wochenschr. 2017; 129(21-22):848-851
Doi: 10.1007/s00508-017-1268-x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Stauber Rudolf
- Co-Autor*innen der Med Uni Graz
- Fauler Günter
- Kessler Harald
- Leber Bettina
- Mangge Harald
- Rainer Florian
- Spindelböck Walter Johann
- Stadlbauer-Köllner Vanessa
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Direct acting antiviral (DAA)-based treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir (OBV/PTV/r ± DSV) is highly effective in HCV genotype 1 or 4 infection and well-tolerated with only few side effects. However, pruritus has been observed in several trials in up to 20% of patients and seems to be unique for this DAA combination. The aim of this preliminary study was to investigate the effect of OBV/PTV/r ± DSV on bile acid levels and to correlate them to the emergence of pruritus during treatment. Twenty patients with chronic hepatitis C genotype 1 or 4 were treated for 12 or 24 weeks with OBV/PTV/r ± DSV with or without ribavirin. Side effects including pruritus were assessed every 4 weeks during treatment or on demand. Blood was collected in fasting state at baseline and at treatment week 4 for determination of bile acid concentrations by high-resolution mass spectrometry. Pruritus developed in 5 out of 20 patients during the first 4 weeks of DAA treatment. Pruritus was self-limiting during DAA treatment in 4 patients while one patient required cholestyramine treatment and responded well. Total bile acid levels increased approximately 4‑fold by treatment week 4. Pruritus observed during OBV/PTV/r ± DSV treatment of chronic hepatitis C is associated with increased on-treatment serum bile acid levels, possibly due to ritonavir-induced alterations of bile acid transport.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Anilides - adverse effects
- Anilides - therapeutic use
- Bile Acids and Salts - blood
- Carbamates - adverse effects
- Carbamates - therapeutic use
- Drug Therapy, Combination -
- Female -
- Genotype -
- Hepacivirus - drug effects
- Hepacivirus - genetics
- Hepatitis C, Chronic - blood
- Hepatitis C, Chronic - drug therapy
- Humans -
- Macrocyclic Compounds - adverse effects
- Macrocyclic Compounds - therapeutic use
- Male -
- Middle Aged -
- Pruritus - blood
- Pruritus - chemically induced
- Ritonavir - adverse effects
- Ritonavir - therapeutic use
- Sulfonamides - adverse effects
- Sulfonamides - therapeutic use
- Uracil - adverse effects
- Uracil - analogs & derivatives
- Uracil - therapeutic use
- Find related publications in this database (Keywords)
- Chronic hepatitis C
- Direct acting antivirals
- Pruritus
- Bile acids